Providing expertise in the analysis of biomarkers in preclinical and clinical development.
Biomarkers are now an integral part of industry efforts to streamline drug development. They are increasingly important in helping "go/no go" decisions in early phase preclinical and clinical development, either as indicators of safety or efficacy.
We are able to manage complex biomarker challenges and develop new methods. Our breadth of capabilities span from biomarker discovery, assay development, validation and sample analysis supporting preclinical and clinical development programmes.
Download our white paper: Biomarkers in Rheumatoid Arthritis (RA)
Our biomarker services can be adapted to your drug development, drug surveillance or other clinical research or monitoring needs.
GCP - Good Clinical Practice; GLP - Good Laboratory Practice; BioMS™ - Biologicals measured by mass spectrometry; MSD™ - Meso Scale Discovery